CSL have a market cap of $140 billion. Last year, Imugene hit a market cap of over $4 billion (fully diluted) - equivalent to about $25 a share for RAC - on seemingly nothing but hype. The market will find the money for the right story.
Pursuing an overseas listing is likely to be a distraction with no guarantee of success rather than a quick panacea for the share price. We'll be better off with RAC management focusing on execution (i.e. getting the story right) - commencing (the right) trials, recruiting patients, obtaining clinical results, pursuing partnerships, etc.
Ann: Ethics submission to commence cardioprotection trial, page-17
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |